Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.

Mehta R, Farrell C, Hayes S, Birk R, Okour M, Lipson DA.

Clin Pharmacokinet. 2019 Jul 19. doi: 10.1007/s40262-019-00794-w. [Epub ahead of print]

PMID:
31321713
2.

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.

Lancet Respir Med. 2019 Jul 4. pii: S2213-2600(19)30190-0. doi: 10.1016/S2213-2600(19)30190-0. [Epub ahead of print]

PMID:
31281061
3.

Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.

Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I.

Pulm Pharmacol Ther. 2019 Aug;57:101802. doi: 10.1016/j.pupt.2019.101802. Epub 2019 May 13.

4.

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.

Naya I, Tombs L, Lipson DA, Boucot I, Compton C.

Respir Res. 2019 Mar 26;20(1):60. doi: 10.1186/s12931-019-1027-9.

5.

Soil microbial responses to drought and exotic plants shift carbon metabolism.

Pérez Castro S, Cleland EE, Wagner R, Sawad RA, Lipson DA.

ISME J. 2019 Jul;13(7):1776-1787. doi: 10.1038/s41396-019-0389-9. Epub 2019 Mar 14.

PMID:
30872806
6.

Preventing clinically important deterioration with single-inhaler triple therapy in COPD.

Naya I, Compton C, Ismaila AS, Birk R, Brealey N, Tabberer M, Zhu CQ, Lipson DA, Criner G.

ERJ Open Res. 2018 Oct 3;4(4). pii: 00047-2018. doi: 10.1183/23120541.00047-2018. eCollection 2018 Oct.

7.

The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).

Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA.

COPD. 2018 Jun-Aug;15(4):334-340. doi: 10.1080/15412555.2018.1481022. Epub 2018 Sep 28.

PMID:
30265816
8.

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis.

Naya IP, Tombs L, Lipson DA, Compton C.

Adv Ther. 2018 Oct;35(10):1626-1638. doi: 10.1007/s12325-018-0771-4. Epub 2018 Sep 6.

9.

Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Criner GJ, Lomas DA.

N Engl J Med. 2018 Aug 9;379(6):592-593. doi: 10.1056/NEJMc1807380. No abstract available.

PMID:
30089077
10.

Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials.

Ray R, Tombs L, Asmus MJ, Boucot I, Lipson DA, Compton C, Naya I.

Drugs Aging. 2018 Jul;35(7):637-647. doi: 10.1007/s40266-018-0558-y.

11.

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.

Mehta R, Pefani E, Beerahee M, Brealey N, Barnacle H, Birk R, Zhu CQ, Lipson DA.

J Clin Pharmacol. 2018 Nov;58(11):1461-1467. doi: 10.1002/jcph.1253. Epub 2018 May 15.

12.

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses.

Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, Lomas DA, Zhu CQ, Lipson DA.

ERJ Open Res. 2018 May 4;4(2). pii: 00119-2017. doi: 10.1183/23120541.00119-2017. eCollection 2018 Apr.

13.

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators.

N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.

14.
15.

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study.

Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L.

ERJ Open Res. 2018 Jan 5;4(1). pii: 00073-2017. doi: 10.1183/23120541.00073-2017. eCollection 2018 Jan.

16.

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.

17.

Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 May 1;197(9):1230-1231. doi: 10.1164/rccm.201711-2313LE. No abstract available.

PMID:
29241016
18.

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.

Adv Ther. 2017 Nov;34(11):2518-2533. doi: 10.1007/s12325-017-0626-4. Epub 2017 Nov 1.

19.

A communal catalogue reveals Earth's multiscale microbial diversity.

Thompson LR, Sanders JG, McDonald D, Amir A, Ladau J, Locey KJ, Prill RJ, Tripathi A, Gibbons SM, Ackermann G, Navas-Molina JA, Janssen S, Kopylova E, Vázquez-Baeza Y, González A, Morton JT, Mirarab S, Zech Xu Z, Jiang L, Haroon MF, Kanbar J, Zhu Q, Jin Song S, Kosciolek T, Bokulich NA, Lefler J, Brislawn CJ, Humphrey G, Owens SM, Hampton-Marcell J, Berg-Lyons D, McKenzie V, Fierer N, Fuhrman JA, Clauset A, Stevens RL, Shade A, Pollard KS, Goodwin KD, Jansson JK, Gilbert JA, Knight R; Earth Microbiome Project Consortium.

Nature. 2017 Nov 23;551(7681):457-463. doi: 10.1038/nature24621. Epub 2017 Nov 1.

20.

Reply to Suissa and Ariel: The FULFIL Trial.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):542-543. doi: 10.1164/rccm.201709-1831LE. No abstract available.

PMID:
28950068

Supplemental Content

Loading ...
Support Center